Skip to Main Content

A pivotal moment for BioCryst Pharmaceuticals (BCRX) is approaching.

In the next few months, the Durham, N.C.-based biotech will announce results from a Phase 3 clinical trial of its lead drug targeting a rare, genetic disease called hereditary angioedema. The outcome of the study is super important for BioCryst. Positive results mean a likely marketing approval and hundreds of millions of dollars in sales. If the study fails, BioCryst’s drug-development efforts start from scratch.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!